Recently, the Phase III Prostate Adenocarcinoma TransCutaneous Hormone (PATCH; ClinicalTrials.gov identifier NCT00303784) and Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE; NCT00268476) trials demonstrated that in addition to similar castration rates, men treated with tE2 patches have non‐inferior prostate cancer outcomes in comparison to men treated with subcutaneous LHRH analogues [6]. The gene discussed is GNRH1; the disease is prostate carcinoma.